Shenzhen Salubris Pharmaceuticals Co Ltd (002294) — Financial Flexibility Index
Shenzhen Salubris Pharmaceuticals Co Ltd (002294) has a Financial Flexibility Index of 0.34x as of September 2025. Free cash flow of CN¥692.94 Million (operating CF CN¥400.70 Million minus capex CN¥292.24 Million) represents 0% of total liabilities (CN¥2.05 Billion). Check 002294 PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Shenzhen Salubris Pharmaceuticals Co Ltd Financial Flexibility Index (2006–2024)
Historical Financial Flexibility Index trend for Shenzhen Salubris Pharmaceuticals Co Ltd across 19 annual periods. See 002294 working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for Shenzhen Salubris Pharmaceuticals Co Ltd (2006–2024)
Year-by-year free cash flow to debt coverage for Shenzhen Salubris Pharmaceuticals Co Ltd. For the full company profile including market capitalisation, see Shenzhen Salubris Pharmaceuticals Co Ltd (002294) total market value.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | 1.06x | CN¥1.81 Billion | CN¥1.19 Billion | CN¥1.71 Billion | ▼ -8.0% |
| 2023 | 1.15x | CN¥1.54 Billion | CN¥869.79 Million | CN¥1.34 Billion | ▲ +30.2% |
| 2022 | 0.88x | CN¥1.57 Billion | CN¥970.80 Million | CN¥1.78 Billion | ▼ -36.6% |
| 2021 | 1.39x | CN¥1.67 Billion | CN¥1.18 Billion | CN¥1.20 Billion | ▼ -8.4% |
| 2020 | 1.52x | CN¥2.02 Billion | CN¥1.37 Billion | CN¥1.33 Billion | ▼ -17.4% |
| 2019 | 1.84x | CN¥1.96 Billion | CN¥1.51 Billion | CN¥1.07 Billion | ▲ +13.7% |
| 2018 | 1.62x | CN¥1.67 Billion | CN¥1.34 Billion | CN¥1.03 Billion | ▼ -36.1% |
| 2017 | 2.54x | CN¥1.79 Billion | CN¥1.46 Billion | CN¥705.86 Million | ▲ +62.1% |
| 2016 | 1.56x | CN¥1.68 Billion | CN¥1.43 Billion | CN¥1.07 Billion | ▼ -16.3% |
| 2015 | 1.87x | CN¥1.29 Billion | CN¥1.06 Billion | CN¥691.25 Million | ▲ +30.8% |
| 2014 | 1.43x | CN¥1.18 Billion | CN¥982.25 Million | CN¥827.95 Million | ▼ -33.7% |
| 2013 | 2.16x | CN¥1.10 Billion | CN¥668.52 Million | CN¥508.36 Million | ▼ -0.2% |
| 2012 | 2.16x | CN¥807.96 Million | CN¥521.21 Million | CN¥374.02 Million | ▲ +27.8% |
| 2011 | 1.69x | CN¥524.92 Million | CN¥272.32 Million | CN¥310.52 Million | ▲ +27.6% |
| 2010 | 1.33x | CN¥410.13 Million | CN¥186.65 Million | CN¥309.50 Million | ▼ -27.1% |
| 2009 | 1.82x | CN¥269.96 Million | CN¥134.28 Million | CN¥148.59 Million | ▲ +89.9% |
| 2008 | 0.96x | CN¥139.37 Million | CN¥77.89 Million | CN¥145.70 Million | ▲ +58.3% |
| 2007 | 0.60x | CN¥66.46 Million | CN¥52.75 Million | CN¥109.98 Million | ▲ +45.3% |
| 2006 | 0.42x | CN¥21.71 Million | CN¥12.00 Million | CN¥52.19 Million | — |